Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (NCT04919811)

🧪 Interventions in This Study

• Taletrectinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (77 Sites)

Showing the first 25 of 77 sites.

• Beverly Hills Cancer Center — Beverly Hills, California
• The Oncology Institute of Hope and Innovation — Glendale, California
• Moores Cancer Center at UC San Diego — La Jolla, California
• Keck Medicine of University of Southern California — Los Angeles, California
• UCI Medical Center — Orange, California
• Ventura County Hematology-Oncology Specialists — Oxnard, California
• SCRI - Florida Cancer Specialists South — Fort Meyers, Florida
• Memorial Cancer Institute at Memorial Hospital East — Hollywood, Florida
• Cancer Specialists of North Florida — Jacksonville, Florida
• Memorial Cancer Institute at Memorial Hospital West — Pembroke Pines, Florida
• SCRI - Hematology Oncology Clinic — Baton Rouge, Louisiana
• Mayo Clinic — Rochester, Minnesota
• Center for Cancer Research — Brick, New Jersey
• Cleveland Clinic Foundation — Cleveland, Ohio
• SCRI - Tennessee Oncology — Nashville, Tennessee
• Texas Oncology, P.A. — Dallas, Texas
• Renovatio Clinical — El Paso, Texas
• MD Anderson Cancer Center — Houston, Texas
• Renovatio Clinical — The Woodlands, Texas
• Northwest Medical Specialties, PLLC — Tacoma, Washington
• Princess Margaret Cancer Centre — Toronto, Ontario
• McGill University Health Centre Research Institute — Montreal, Quebec
• Beijing Cancer Hospital — Beijing, Beijing Municipality
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan
• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non Small Cell Lung Cancer

• The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
• A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
• Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas

Explore by condition: All Non Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.